"studyDesignRationale","description","name","id","label","uuid:ID"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1","StudyDesign_1","","0a9d7853-e87b-4031-920a-1145ba769bb4"
